FibroGen (NASDAQ: FGEN)
Key Data Points
FibroGen Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
FibroGen Company Info
FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.
News & Analysis
Down 80% in 1 Day, Is There Any Hope for FibroGen Stock?
Its pipeline is looking thin, and it might hit another speed bump quite soon.
Why FibroGen Fell by More Than 9% on Wednesday
A noted investment bank takes a dimmer view of the company's stock.
What's Next for FibroGen After an FDA Vote Against Its Anemia Drug?
FDA approval of roxadustat seems unlikely.
Here's Why FibroGen Stock Is Plunging Today
An FDA advisory committee made it clear that they don't want the agency to approve roxadustat due to safety concerns.
Why FibroGen Stock Is Crashing Today
The company disclosed a bombshell related to its safety results for lead candidate roxadustat.
Why FibroGen Got Mashed on Monday
The FDA delivered a discouraging update in time for the holidays.
FibroGen's Anemia Drug Goes to FDA for Review
A decision on Roxadustat should arrive by Dec. 20.
FibroGen Appoints Enrique Conterno as Its New CEO
The former Eli Lilly executive will be tasked with launching the biotech's anemia drug roxadustat.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.